Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) shares were down 6.1% during mid-day trading on Thursday . The stock traded as low as $20.33 and last traded at $20.11. Approximately 84,052 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 822,430 shares. The stock had previously closed at $21.42.
Wall Street Analysts Forecast Growth
Several equities research analysts recently issued reports on GPCR shares. Stifel Nicolaus started coverage on shares of Structure Therapeutics in a research report on Wednesday, January 8th. They issued a "buy" rating and a $50.00 target price on the stock. William Blair assumed coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They issued an "outperform" rating on the stock. JMP Securities reaffirmed a "market outperform" rating and set a $91.00 price target on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Finally, HC Wainwright reissued a "buy" rating and issued a $80.00 price objective on shares of Structure Therapeutics in a research report on Thursday, December 19th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $81.29.
Read Our Latest Analysis on Structure Therapeutics
Structure Therapeutics Stock Performance
The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of -28.45 and a beta of -2.35. The firm has a fifty day moving average of $25.31 and a 200-day moving average of $32.38.
Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01. On average, analysts predict that Structure Therapeutics Inc. will post -0.82 EPS for the current year.
Hedge Funds Weigh In On Structure Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its position in Structure Therapeutics by 0.7% in the 3rd quarter. Geode Capital Management LLC now owns 45,225 shares of the company's stock valued at $1,985,000 after buying an additional 312 shares during the last quarter. Virtus ETF Advisers LLC boosted its position in Structure Therapeutics by 25.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock valued at $61,000 after buying an additional 455 shares during the last quarter. ANTIPODES PARTNERS Ltd boosted its position in Structure Therapeutics by 115.0% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock valued at $28,000 after buying an additional 553 shares during the last quarter. LPL Financial LLC boosted its position in Structure Therapeutics by 6.0% in the 4th quarter. LPL Financial LLC now owns 11,485 shares of the company's stock valued at $311,000 after buying an additional 646 shares during the last quarter. Finally, Assetmark Inc. boosted its position in Structure Therapeutics by 120.0% in the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company's stock valued at $58,000 after buying an additional 719 shares during the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.
About Structure Therapeutics
(
Get Free Report)
Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
Further Reading
Before you consider Structure Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.
While Structure Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
